Related Experiment Video
Updated: Aug 14, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
The general practitioner pharmacotherapy prescribing workforce: examining sustainability from a systems perspective
Elizabeth Hotham1, Ann Roche, Natalie Skinner
1National Centre for Education and Training on Addiction, Flinders University, South Australia.
Drug and Alcohol Review
|November 22, 2005
Summary
Australian general practitioners (GPs) face challenges in opioid pharmacotherapy services, with a small prescriber base and high attrition rates. Strategies are needed to recruit, support, and retain these essential healthcare professionals for sustainable treatment.
Area of Science:
- Addiction Medicine
- Health Workforce Research
- General Practice
Background:
- General practitioners (GPs) are crucial for opioid pharmacotherapy services.
- The sustainability of these services relies heavily on the GP prescriber workforce.
- Understanding the dynamics of this workforce is vital for effective policy and program development.
Purpose of the Study:
- To examine the nature and sustainability of the Australian GP prescriber workforce for opioid pharmacotherapies.
- To identify key challenges and characteristics of GP prescribers in four Australian states.
- To inform future workforce development strategies and policy decisions.
Main Methods:
- Analysis of data from South Australia, Queensland, Victoria, and New South Wales.
- Examination of prescriber load, activity status, and training attrition rates.
- Assessment of prescriber availability relative to patient population needs.
Main Results:
- A small number of GPs manage a heavy client load in opioid pharmacotherapy.
- A significant proportion of trained GPs remain inactive, and many do not commence prescribing after training (high attrition).
- Substantial shortfalls exist in the number of available prescribers across the studied states.
Conclusions:
- Urgent workforce development strategies are required to ensure sustainable, high-quality opioid pharmacotherapy services.
- Focus should be on recruiting new prescribers and supporting/retaining existing and inactive ones.
- Prioritizing systematic and detailed data collection systems for this workforce is essential.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...